|Table of Contents|

Survival analysis of patients with advanced EGFR 21 L858R lung adenocarcinoma treated with targeted therapy alone or in combination with targeted therapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4362-4366
Research Field:
Publishing date:

Info

Title:
Survival analysis of patients with advanced EGFR 21 L858R lung adenocarcinoma treated with targeted therapy alone or in combination with targeted therapy
Author(s):
HE Jiao; HAN Zhigang; YU Tingting
The Third Affiliated Hospital of Xinjiang Medical University，Xinjiang Urumqi 830011,China.
Keywords:
real world research; lung adenocarcinoma; L858R mutation; targeted therapy; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.23.012
Abstract:
Objective:To evaluate the efficacy and safety differences between targeted alone or targeted combination therapy in real-world patients with advanced EGFR 21 L858R lung adenocarcinoma and to analyze the factors affecting progression-free survival(PFS) and overall survival(OS).Methods:The clinical characteristics,treatment effects,safety and survival data of 109 patients with advanced EGFR 21 L858R lung adenocarcinoma diagnosed in our hospital from January 2015 to December 2019 were retrospectively analyzed using SPSS 26.0 software.Results:Median PFS and median OS were significantly better in the targeted combination therapy group than in the targeted therapy alone group(mPFS:14.5 months vs 10.3 months,P＜0.05,mOS:31.9 months vs 24.6 months,P＜0.05).There was no statistically significant difference in ORR(54.4% vs 38.5%) and DCR(96.5% vs 94.2%) between the two groups,but the targeted combination therapy improved the ORR of patients to some extent and showed a better objective remission rate.Analysis of patients' baseline data revealed that tumor size at initial treatment,treatment modality,pre-treatment carcinoembryonic antigen(CEA) and cytokeratin 19(CYFRA21-1) levels were independent prognostic factors for disease progression,while age,presence of brain metastases at initial treatment,treatment modality,glycoantigen 125(CA125) and cytokeratin 19(CYFRA21-1) levels could affect patients' OS.In a safety comparison,the most common adverse effect of targeted therapy alone was rash,followed by gastrointestinal reactions.The most common adverse effect of targeted combination therapy was gastrointestinal reaction,followed by bone marrow suppression.Overall,the two groups were well tolerated,but the incidence of adverse reactions in the targeted combination therapy group(68.4%) was significantly higher than that in the targeted therapy alone group(38.5%),and the difference was statistically significant(P＜0.001).Conclusion:Patients with advanced lung adenocarcinoma with EGFR 21 L858R mutation were better treated with targeted combination therapy than with targeted therapy alone,and were well tolerated.Tumor size at initial treatment and levels of tumor-associated antigens(CEA and CYFRA21-1) before treatment were independent prognostic factors for PFS,and age,presence of brain metastases at initial treatment,and levels of tumor-associated antigens(CYFRA21-1 and CA125) could affect OS of patients.

References:

[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] LI D,DING L,RAN W,et al.Status of 10 targeted genes of non-small cell lung cancer in eastern china:A study of 884 patients based on NGS in a single institution［J］.Thoracic Cancer,2020,11(9):2580-2589.
[3] MANSUET-LUPO A,ALIFANO M,PECUCHET N,et al.Intratumoral immune cell densities are associated with lung adenocarcinoma gene alterations［J］.American Journal of Respiratory and Critical Care Medicine,2016,194(11):1403-1412.
[4] KOMURCUOGLU B,KARAKURT G,KAYA O,et al.Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer［J］.Journal of Cancer Research and Therapeutics,2023,19(8):183.
[5] HAN B,TJULANDIN S,HAGIWARA K,et al.EGFR mutation prevalence in asia-pacific and russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology:the ignite study［J］.Lung Cancer(Amsterdam,Netherlands),2017,113:37-44.
[6] CHUNG C.Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers:an update for recent advances in therapeutics［J］.Journal of Oncology Pharmacy Practice,2016,22(3):461-476.
[7] CHOI YW,JEON SY,JEONG GS,et al.EGFR exon 19 deletion is associated with favorable overall survival after first-line gefitinib therapy in advanced non-small cell lung cancer patients［J］.American Journal of Clinical Oncology,2018,41(4):385-390.
[8] ROSSI S,D' ARGENTO E,BASSO M,et al.Different EGFR gene mutations in exon 18,19 and 21 as prognostic and predictive markers in NSCLC:a single institution analysis［J］.Molecular Diagnosis & Therapy,2016,20(1):55-63.
[9] WANG H,HUANG J,YU X,et al.Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer:a meta-analysis［J］.Journal of Cancer Research and Clinical Oncology,2014,140(11):1901-1909.
[10] JIANG H,ZHU M,LI Y,et al.Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer［J］.Molecular and Clinical Oncology,2019,11(3):301-308.
[11] SABBAH DA,HAJJO R,SWEIDAN K.Review on epidermal growth factor receptor(EGFR) structure,signaling pathways,interactions,and recent updates of EGFR inhibitors［J］.Current Topics in Medicinal Chemistry,2020,20(10):815-834.
[12] KARLSEN EA,KAHLER S,TEFAY J,et al.Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer:a review［J］.Cells,2021,10(5):1206.
[13] LEIGHL NB,REKHTMAN N,BIERMANN WA,et al.Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors:American society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline［J］.Journal of Clinical Oncology,2014,32(32):3673-3679.
[14] SHARMA N,GRAZIANO S.Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer［J］.Cancer Treatment Reviews,2018,69:143-151.
[15] CHENG Y,HE Y,LI W,et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC:FLAURA china,a randomized study［J］.Targeted Oncology,2021,16(2):165-176.
[16] OIZUMI S,SUGAWARA S,MINATO K,et al.Updated survival outcomes of NEJ005/TCOG0902:a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations［J］.Esmo Open,2018,3(2):e000313.
[17] MIYAUCHI E,MORITA S,NAKAMURA A,et al.Updated analysis of NEJ009:gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR［J］.Journal of Clinical Oncology,2022,40(31):3587-3592.
[18] WANG J,LIU H,SUN X,et al.Correlation between circulating tumor cells and plasma D-dimer and clinicopathological characteristics of patients with non-small cell lung cancer［J］.Journal of the College of Physicians and Surgeons-Pakistan,2021,30(4):417-421.
[19] MOTONO N,MATSUI T,MACHIDA Y,et al.Prognostic significance of histologic subtype in pstage Ⅰ lung adenocarcinoma［J］.Medical Oncology(Northwood,London,England),2017,34(6):100.
[20] GRUNNET M,SORENSEN JB.Carcinoembryonic antigen(CEA) as tumor marker in lung cancer［J］.Lung Cancer(Amsterdam,Netherlands),2012,76(2):138-143.
[21] SPERDUTO PW,YANG TJ,BEAL K,et al.Estimating survival in patients with lung cancer and brain metastases:an update of the graded prognostic assessment for lung cancer using molecular markers(Lung-molGPA)［J］.JAMA Oncology,2017,3(6):827.

Memo

Memo:
新疆维吾尔族自治区自然科学基金资助项目（编号：2022D01C522）
Last Update: 2023-10-31